Breaking News Instant updates and real-time market news.

ASMB

Assembly Biosciences

$9.31

0.31 (3.44%)

16:10
10/15/19
10/15
16:10
10/15/19
16:10

Assembly Biosciences initiated with a Buy at Mizuho

Mizuho started Assembly Biosciences with a Buy rating and $20 price target.

  • 29

    Oct

  • 30

    Oct

ASMB Assembly Biosciences
$9.31

0.31 (3.44%)

11/13/18
JEFF
11/13/18
NO CHANGE
Target $75
JEFF
Buy
Assembly Biosciences shares likely to rally into Phase II data, says Jefferies
Jefferies analyst Michael Yee sees shares of Assembly Biosciences "going back up" into new its Phase II data in the first half of 2019. The company continues to execute on its vision to develop first-in-class and best-in-class core inhibitors, Yee tells investors in a research note. He says that while Street expectations have been lowered on Hepatitis B virus in the past year, interest among key opinion leaders has "only increased as data has been presented and has been notable." The analyst keeps a Buy rating on Assembly Biosciences with a $75 price target.
11/19/18
LEER
11/19/18
INITIATION
Target $45
LEER
Outperform
Assembly Biosciences initiated with an Outperform at Leerink
Leerink analyst Geoffrey Porges started Assembly Biosciences with an Outperform rating and $45 price target. The analyst cited the probability-adjusted value for the cash flows he expects from its lead asset ABI-H0731, which is an oral Core Protein Allosteric Modifier in phase II development for chronic hepatitis B virus. Porges forecasts '731 launching in 2022E and growing to $650M in risk-adjusted revenues.
04/15/19
JMPS
04/15/19
NO CHANGE
Target $116
JMPS
Outperform
Enanta early data on EDP-514 look promising, says JMP Securities
JMP Securities analyst Liisa Bayko said she was impressed with the preclinical data presented by Enanta (ENTA) at the EASL meeting on its HBV core inhibitor candidate EDP-514. When comparing to other core inhibitors in development, EDP-514 "appears at least as potent as the competition" with the exception of Assembly Biosciences' (ASMB) third-generation capsid inhibitor ABI-H3733, said Bayko, who added that EDP-514 has a superior reduction in HBV viral load than ABI-H3733 and a lower EC50 level than Assembly's first- and second-generation inhibitors. Bayko keeps an Outperform rating and $116 price target on Enanta shares.
07/16/19
JEFF
07/16/19
NO CHANGE
Target $30
JEFF
Buy
Assembly competitor data further validates class, says Jefferies
The initial hepatitis B virus data by Arbutus Biopharma (ABUS) further validates the class showing "efficacy" consistent with Assembly Bioscience (ASMB) and others, Jefferies analyst Michael Yee tells investors in a research note. The analyst continues to believe the capsid class is active and will play a role in a future hepatitis B virus combination. He believes stocks with exposure "remain cheap" and keeps a Buy rating on Assembly Biosciences with a $30 price target.

TODAY'S FREE FLY STORIES

PAYC

Paycom

$239.80

4.63 (1.97%)

06:39
11/20/19
11/20
06:39
11/20/19
06:39
Upgrade
Paycom rating change  »

Paycom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

QCOM

Qualcomm

$87.95

-2.52 (-2.79%)

06:39
11/20/19
11/20
06:39
11/20/19
06:39
Recommendations
Qualcomm analyst commentary  »

Qualcomm positioned well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

06:38
11/20/19
11/20
06:38
11/20/19
06:38
Hot Stocks
Breaking Hot Stocks news story on Target »

Target up 8.3% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

AVY

Avery Dennison

$131.42

0.26 (0.20%)

06:38
11/20/19
11/20
06:38
11/20/19
06:38
Hot Stocks
Avery Dennison to acquire Smartrac's RFID Inlay business for EUR225M »

Avery Dennison announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

06:37
11/20/19
11/20
06:37
11/20/19
06:37
Earnings
Breaking Earnings news story on Target »

Target raises FY19 adj…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

ADSK

Autodesk

$164.53

2.08 (1.28%)

06:37
11/20/19
11/20
06:37
11/20/19
06:37
Recommendations
Autodesk analyst commentary  »

Autodesk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

QIWI

Qiwi

$20.14

0.38 (1.92%)

06:36
11/20/19
11/20
06:36
11/20/19
06:36
Earnings
Qiwi raises FY19 adjusted revenue growth view to 15%-19% from 9%-15% »

Consensus for FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

TGT

Target

$110.86

0.27 (0.24%)

06:35
11/20/19
11/20
06:35
11/20/19
06:35
Earnings
Target sees Q4 adj. EPS $1.54-$1.75, consensus $1.65 

Sees Q4 SSS up 3%-4%.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TJX

TJX

$60.66

1.12 (1.88%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Recommendations
TJX analyst commentary  »

Nomura Instinet lists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

T

AT&T

$38.00

-1.61 (-4.06%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Recommendations
AT&T analyst commentary  »

KeyBanc data shows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

LLY

Eli Lilly

$115.13

1.04 (0.91%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Hot Stocks
Eli Lilly to invest $400M in Indianapolis manufacturing facilities »

Eli Lilly announced plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 30

    Jan

TGT

Target

$110.86

0.27 (0.24%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Earnings
Target reports Q3 adj. EPS $1.36, consensus $1.19 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CDXC

ChromaDex

$3.49

0.19 (5.76%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Hot Stocks
ChromaDex: EC votes in favor on Nicotinamide Riboside Chloride as a novel food »

ChromaDex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QIWI

Qiwi

$20.14

0.38 (1.92%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Earnings
Qiwi reports Q3 EPS 29c, one estimate 33c »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

EVRG

Evergy

$64.79

-0.19 (-0.29%)

06:29
11/20/19
11/20
06:29
11/20/19
06:29
Downgrade
Evergy rating change  »

Evergy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$3.84

-0.015 (-0.39%)

06:26
11/20/19
11/20
06:26
11/20/19
06:26
Downgrade
RPC, Inc. rating change  »

RPC, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$5.63

-0.295 (-4.98%)

06:24
11/20/19
11/20
06:24
11/20/19
06:24
Downgrade
Qudian rating change  »

Qudian downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

06:22
11/20/19
11/20
06:22
11/20/19
06:22
Periodicals
WeWork began layoffs on Monday, Business Insider reports »

WeWork's layoffs…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

06:21
11/20/19
11/20
06:21
11/20/19
06:21
Downgrade
Berry Petroleum rating change  »

Wells Fargo downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBCP

Concrete Pumping

$3.88

0.17 (4.58%)

06:21
11/20/19
11/20
06:21
11/20/19
06:21
Conference/Events
Concrete Pumping management to meet with William Blair »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

EVRG

Evergy

$64.79

-0.19 (-0.29%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Downgrade
Evergy rating change  »

Evergy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.03

-1.85 (-10.96%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Periodicals
Macy's confirms 'targeted data security incident' impacted customers, WSJ says »

Macy's says customer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

AL

Air Lease

$45.16

0.435 (0.97%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Conference/Events
Air Lease management to meet with Stephens »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

06:19
11/20/19
11/20
06:19
11/20/19
06:19
Downgrade
Berry Petroleum rating change  »

KeyBanc downgrades Berry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XGN

Exagen

$19.25

-0.04 (-0.21%)

06:19
11/20/19
11/20
06:19
11/20/19
06:19
Conference/Events
Exagen management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.